AZNCF - Pfizer's Vaccine Read-Out: What Will Happen To Value Stocks
- Pfizer reported encouraging interim data for its COVID-19 vaccine with a 90% efficacy rate, which makes us hopeful for other read-outs.
- This is the big catalyst for sentiment in value stocks, which have not been this cheap compared to growth stocks in 20 years, to improve.
- In this article, I will discuss why we expect value stocks to keep thriving in the future.
- However, I want to warn investors to not get caught by their emotions during this rally of value stocks. Some of them are very bad long-term investments.
For further details see:
Pfizer's Vaccine Read-Out: What Will Happen To Value Stocks